Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

BACKGROUND: Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotec...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:ESMO Open
Autores principales: Aoki, Masahiko, Shoji, Hirokazu, Nagashima, Kengo, Imazeki, Hiroshi, Miyamoto, Takahiro, Hirano, Hidekazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Higuchi, Kazuhide, Boku, Narikazu
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555603/
https://ncbi.nlm.nih.gov/pubmed/31231567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000488
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares